Deals Shaping the Medical Industry, July 2019
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June 2019.
You may also be interested in...
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
Scrip highlights the key transactions involving Indian firms in 2019. Divestments and licensing were among the prominent themes that dotted the deal landscape in the year gone by.
Merck KGaA and Artios penned a global three-year strategic research collaboration to discover and develop multiple precision oncology drugs. The deal could be worth close to $7bn for four-year-old Artios. AstraZeneca announced a definitive agreement to acquire public rare disease drug developer Alexion for approximately $39bn. This was 2020’s largest M&A. Financing reached $28bn in biopharma, $879m in device, and $2.4bn in diagnostics.